Effect of electroacupuncture on metabolic level and quality of life in patients with obese polycystic ovary syndrome: a randomized controlled trial
Abstract
Objective: This study aims to investigate the effects of electroacupuncture (EA) intervention on patients with obese polycystic ovary syndrome (PCOS), with specific analysis focusing on the following dimensions: 1) whether EA can reduce patients' body mass index (BMI); 2) to evaluate the regulatory effect of EA on key endocrine and metabolic indicators of patients, including blood glucose, blood lipids, and sex hormones; 3) to examine whether EA can improve reproduction-related outcomes in patients, such as abnormal menstrual cycles, abnormal menstrual flow, abnormal endometrial thickness, and ovulatory dysfunction; and 4) to verify the effect of EA in improving patients' quality of life. Furthermore, this study intends to provide evidence-based support for the optimization of clinical non-pharmacological intervention strategies for obese PCOS.
Methods: This was a patient- and assessor-blinded, randomized, sham-controlled trial, enrolling 106 female patients with obese PCOS aged 18-45 years. Participants were randomly assigned to two groups: the EA group and the sham EA group. The treatment duration was 12 weeks, with a 12-week follow-up period after treatment completion. The intervention frequency was adjusted in stages: three sessions/week during Weeks 1-4, two sessions/week during Weeks 5-8, and one session/week during Weeks 9-12, resulting in a total of 24 treatment sessions throughout the entire course. The primary outcome was the change in BMI from baseline to the end…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 106 participants or records.
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.